Loading
HKSEHealthcareBiotechnology
Latest quote
HK$13.52
+HK$0.26 · +1.96%
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
Latest quote
HK$13.52
+HK$0.26 · +1.96%
Regular session · HKT · Market data may be delayed.
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
Day range
Current HK$13.52
52-week range
Current HK$13.52
Regular session · HKT · Market data may be delayed.
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
Day range
Current HK$13.52
52-week range
Current HK$13.52
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 125.66M CNY | 39.43M CNY | — | — | 25.81M CNY |
| Cost of goods sold | 45.71M CNY | 24.68M CNY | — | — | — |
| Gross profit | 79.95M CNY | 14.75M CNY | — | — | 25.81M CNY |
| Research and development | 245.36M CNY | 466.19M CNY | 661.66M CNY | 680.3M CNY | 501.72M CNY |
| Selling, general, and administrative | 71.81M CNY | 162.84M CNY | 133.31M CNY | 136.61M CNY | 126.52M CNY |
| Operating expenses | 184.16M CNY | 822.94M CNY | 767.65M CNY | 881.3M CNY | 599.72M CNY |
| Interest income | 14.81M CNY | 41.92M CNY | 72.79M CNY | 27.57M CNY | 9.61M CNY |
| Interest expense | 6.9M CNY | 5.71M CNY | 4.66M CNY | 15.52M CNY | 10.87M CNY |
| Depreciation and amortization | 23.99M CNY | 65.14M CNY | 67.41M CNY | 56.92M CNY | 34.91M CNY |
| Operating income | −104.21M CNY | −808.19M CNY | −767.65M CNY | −881.3M CNY | −573.91M CNY |
| Net income | −97.86M CNY | −798.13M CNY | −747.79M CNY | −892.25M CNY | −4.74B CNY |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS8.91M0.00%646.2B USD0.05%$88.41+0.50%
Vanguard FTSE Emerging Markets ETFVWO8.46M0.01%162.3B USD0.06%$61.44+0.74%
iShares Core MSCI Emerging Markets ETFIEMG5.84M0.00%163.85B USD0.09%$83.65+1.65%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS2.57M0.02%13.6B USD0.06%$161.34+0.42%
State Street SPDR Portfolio Emerging Markets ETFSPEM897.78K0.01%17.77B USD0.07%$53.41+0.77%
Vanguard Total World Stock ETFVT510.58K0.00%97.9B USD0.06%$161.73-0.02%
iShares Core MSCI Total International Stock ETFIXUS363.97K0.00%61.15B USD0.07%$98.71+0.57%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX297.04K0.04%680.67M USD0.65%$74.065+0.75%Vanguard Total International Stock ETFVXUSVanguard FTSE Emerging Markets ETFVWOiShares Core MSCI Emerging Markets ETFIEMGVanguard FTSE All-World ex-US Small-Cap ETFVSSState Street SPDR Portfolio Emerging Markets ETFSPEMVanguard Total World Stock ETFVTiShares Core MSCI Total International Stock ETFIXUSState Street SPDR S&P Emerging Markets Small Cap ETFEWXAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
